Your Basket is currently empty

Your Bookshelf is empty!

Your Basket is currently empty


Banner

Evergreening Patent Exclusivity in Pharmaceutical Products

Supplementary Protection Certificates, Orphan Drugs, Paediatric Extensions and ATMPs

By: Frantzeska Papadopoulou
Media of Evergreening Patent Exclusivity in Pharmaceutical Products
See larger image
Published: 21-10-2021
Format: Hardback
Edition: 1st
Extent: 368
ISBN: 9781509950287
Imprint: Hart Publishing
Dimensions: 234 x 156 mm
RRP: £90.00
Online price : £81.00
Save £9.00 (10%)
 

: (?)

Buying pre-order items

Your pre-order item will usually be shipped on the publishing date of the book.

Ebooks

You will receive an email with a download link for the ebook on the publication date.

Payment

You will not be charged for pre-ordered books until they are available to be shipped. Pre-ordered ebooks will not be charged for until they are available for download.

Amending or cancelling your order

For orders that have not been shipped you can usually make changes to pre-orders up to 24 hours before the publishing date.

This book is also available in other formats: View formats

Delivery & Returns

Tell others about this product

Loren Epson

About Evergreening Patent Exclusivity in Pharmaceutical Products

This book analyses 4 central pieces of EU pharmaceutical regulation: the Orphan Drugs Regulation, the Paediatric Regulation, the Supplementary Protection Certificate Regulation, and the ATMP (Advanced Therapy Medicinal Products) Regulation. These four regulatory instruments constitute focal points in the pharmaceutical industry's approach to modern business and legal strategy. Their central role is justified by the way these regulatory instruments interact with each other and with the patent system, and by the considerable impact they (as a whole) have for the evergreening of exclusive rights on pharmaceutical products.

The book guides the reader through the latest case law and legislative developments and discusses how these influence strategic legal and business choices in the pharmaceutical industry. It brings to the forefront the often-overlooked significance of the legislative architecture of the EU pharmaceutical regulatory framework, and evaluates its results through the lens of the efficiency test.

The book is an important resource for academics and practitioners interested in updated case law and an in-depth analysis of these four regulations. It is also important for those interested in legislative studies, evaluation of legislation and a critical approach to legislative architecture.

Table Of Contents

Table of Cases
Table of Legislation

1. Regulating the EU Pharmaceutical Sector: A Multilayer Challenge
1. The Pharmaceutical Sector: A Need for Regulation
2. The Structure of the Pharmaceutical Industry in Europe
3. EU Competence in the Field of Public Health
4. Effective Legislation and Regulatory Rights
5. The Structure of the Book

2. Setting the Stage for Regulatory Rights: The Regulatory Agencies and the Marketing Authorisation Procedure
1. Regulatory Authorities
2. The Marketing Authorisation Procedure
3. Concluding Remarks

3. Data Exclusivity
1. The Legal Framework
2. Clinical Data
3. The Marketing Authorisation Procedure and Directive 2001/83 – Original Pharmaceuticals
4. Marketing Authorisation for Generic Products
5. The Weaknesses of the System
6. Data Exclusivity for Paediatric Medicines That Are Not Patent-Protected
7. Concluding Remarks

4. The Supplementary Protection Certificate
1. Background to the Legal Framework
2. The Legal Framework
3. The Subject of Protection
4. The Rights Granted
5. The SPC Beneficiary
6. Concluding Remarks

5. The Paediatric Extension
1. Background
2. The General Legal Framework
3. A New Committee to Implement the Legal Framework: The Role of the Paediatric Committee (PDCO)
4. The PIP
5. PIP Compliance Control
6. Exemptions and Waivers
7. The Incentives of the Regulation
8. Rewards for Orphan Medicinal Products Under Regulation 1901/2006
9. Other Incentives in the System
10. Post-Approval Obligations
11. Concluding Remarks

6. Orphan Drugs
1. Background to the Legal Framework
2. Procedural Aspects
3. The Criteria for Orphan Drugs Designation
4. Marketing Authorisation of Orphan Drugs
5. The Incentives of the Orphan Drug Designation
6. Post-Grant Obligations of the Sponsor
7. Difficulties in the Interpretation of Orphan Drugs Regulation Case Law
8. Concluding Remarks

7. Advanced Therapy Medicinal Products
1. The Legal Framework
2. Definitions of Key Terms in the ATMP Regulation
3. The ATMP Regulation and Other European Legislation
4. Marketing Authorisation for ATMPs
5. Post-Authorisation Requirements
6. Concluding Remarks

8. How Effective Is the Effectiveness Test in the Field of Regulatory Rights?
1. The Objectives
2. The Contents
3. The Context
4. The Results
5. General Conclusions

Bibliography
Index

Bookmark and Share
Close